A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence

Addiction

Volumn 100, Issue SUPPL. 1, 2005, Pages 32-42

  Reid, Malcolm S ^a   Angrist, Burt ^a   Baker, Sherryl ^c   Woo, Caroline ^a   Schwartz, Marion ^a   Montgomery, Ann ^b   Majewska, Dorota ^b   Robinson, James ^c   Rotrosen, John ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Celecoxib; Cocaine dependence; COX 2; Craving; Treatment

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; BENZOYLECGONINE; CELECOXIB; COCAINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; MYLANTA; NEFAZODONE; PLACEBO; ZOLPIDEM TARTRATE;

ABDOMINAL PAIN; ADDICTION; ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG URINE LEVEL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; MALE; PATIENT COUNSELING; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SCREENING; SELF REPORT; SLEEP DISORDER; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; COCAINE-RELATED DISORDERS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES;

EID: 14944359145     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2005.00989.x     Document Type: Article

References (37)

1. Andreaason, K. I., Savonenko, A., Vidensky, S., Goellner, J. J., Zhang, Y., Shaffer, A., Kaufman, W. E., Worley, P. F., Isakson, P. & Markowska, A. L. (2001) Age-dependent cognitive deficits and neuronal apoptsis in cycooxygenase-2 transgenic mice. Journal of Neuroscience, 21, 8198-8209.
2. Breitner, J. C., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J. & Anthony, J. C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease? The Rotterdam study. Neurology, 44, 227-232.
3. Breitner, J. C., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A., Roses, A. D., Pericak-Vance, M. A. & Saunders, A. M. (1995) Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine blocking drugs. Neurobiology of Aging, 16, 523-530.
4. Bruss, G. S., Gruenberg, A. M., Goldsteinm, R. D. & Barber, J. P. (1994) Hamilton Anxiety Rating Scale Interview guide: joint interview and test-retest methods for interrater reliability. Psychiatry Research, 53, 191-202.
5. Carrol, K. M., Rounsaville, B. J., Gordon, L. T., Nich, C., Jatlow, P., Bisighini, R. M. & Gawin, F. H. (1994) Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Archives of General Psychiatry, 51, 177-187.
6. Cejtin, H. E., Parsons, M. T. & Wilson, L. (1990) Cocaine use and its effect on umbilical prostacyclin production. Prostaglandins, 40, 249-257.
7. Chio, C. L., Drong, R. E., Riley, D. T., Gill, G. S., Slightom, J. L. & Huff, R. M. (1994) D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. Journal of Biological Chemistry, 269, 11,813-11,811,819.
8. Cornish, J. W., Many, A., Fudala, P. J., Neal, S., Poole, S. A., Volpicelli, P. & O'Brien, C. P. (1995) Carbamazepine treatment for cocaine dependence. Drug and Alcohol Dependence, 38, 221-227.
9. Cox, D. R. ( 1972) Regression models and life tables [with Discussion]. Journal of the Royal Statistical Society, 34, 187-202.
10. Emilien, G., Beyreuther, K., Masters, C. L. & Maloteaux, J. M. (2000) Prospects for pharmacological intervention in Alzheimer disease. Archives of Neurology, 57, 454-459.
11. Halikas, J. A., Kuhn, K. L., Crosby, R., Carlson, I. & Crea, F. (1991) The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Comprehensive Psychiatry, 32, 22-27.
12. Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278-296.
13. Kaufman, W. E., Worley, P. F., Pegg, J., Bremer, M. & Isakson, P. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proceedings of the National Academy of Sciences USA, 93, 2317-2321.
14. L'hirondel, M., Cheramy, A., Godeheu, G. & Glowinski, J. (1995) Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. Journal of Neurocheinistry, 64, 1406-1409.
15. Leiderman, D., Shoptaw, S., Montgomery, A., Elkashef, A., Bloch, D., Majewska, D., LoCastro, J. & Vocci, F. (2005) Cocaine Rapid Efficacy Screening Trials (CREST): A paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction, 100, 1-11.
16. Lukiw, W. J. & Bazan, N. G. (2000) Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochemical Research, 9-10, 1173-1184.
17. McAllister, G., Knowles, M. R., Patel, S., Marwood, R., Emms, F., Seabrook, G. R., Graziano, M., Borkowski, D., Hey, P. J. & Freedman, S. B. (1993) Characterization of achimeric D3/D2 dopamine receptor expressed in CHO cells. FEBS Letters, 324, 81-86.
18. McGeer, P. L., Schulzer, M. & McGeer, E. G. (.1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology, 47, 425-432.
19. McLellan, A. T., Luborsky, L., Cacciola, J., Griffith, J., Evans, F., Barr, H. L. & O'Brien, C. P. (1985) New data from the Addiction Severity Index: reliability and validity in three centers. Journal of Nervous and Mental Disease, 173, 412-423.
20. Mezinskis, J., Dyrenforth, S., Goldsmith, R. J. & Somoza, E. (1998) Craving and withdrawal symptoms for various drugs of abuse. Psychiatric Annals, 28, 577-583.
21. Montoya, I. D., Levin, F. R., Fudala, P. J. & Gorelick, D. A. (1995) Double-blind comparison of Carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol Dependence, 38, 213-219.
22. Navaline, H. A., Snider, E. C., Petro, C. J., Tobin, D., Metzger, D., Alterman, A. I. & Woody, G. E. (1994) Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses, 10, S281-S283.
23. Pasinetti, G. M. (1998) Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. Journal of Neuroscience Research, 54, 1-6.
24. Pasinetti, G. M. & Aisen, P. S. (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 87, 319-324,
25. Physicians' Desk Reference (2001) Montvale, NJ: Medical Economics.
26. Reid, M. S., Hsu, K., Tolliver, B. K., Crawford, C. A. & Berger, S. P. (1996) Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. Journal of Pharmacology and Experimental Therapeutics, 276, 1244-1256.
27. Reid, M. S., Ho, L. B., Hsu, K., Fox, L., Tolliver, B. K., Adams, J. U., Franco, A. & Berger, S. P. (2002) Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization. Pharmacology, Biochemistry and Behavior, 71, 37-54.
28. Rogers, J., Kirby, L. C., Hempleman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P. & Kogan, F. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609-1611.
29. Ross, B. M., Moszczynska, A., Kalasinsky, K. & Kish, S. J. (1996) Phospholipase A2 activity is selectively decreased in the stritum of chronic cocaine users. Journal of Neurochemistry, 67, 2620-2623.
30. Sainati, S. M., Ingram, D. M., Talwalker, S. & Geis, G. S. (2000) Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm. Sweden 2000: 180.
31. SAS Institute, Inc. (1990a) SAS/STAT user's Guide, version 6. 4th edition, vol. 1. Cary, NC: SAS Institute.
32. SAS Institute, Inc. (1990b) SAS/STAT user's Guide, version 6. 4th edition, vol. 2. Cary, NC: SAS Institute.
33. Satel, S. L. & Kosten, T. R. (1991) Designing drug efficacy trials in the treatment of cocaine abuse. Journal of Nervous and Mental Disease, 179, 89-96.
34. Tocco, G., Friere-Moar, J., Schreiber, S. S., Sakhi, S. H., Aisen, P. S. & Pasinetti, G. M. (1997) Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Experimental Neurology, 144, 339-349.
35. Tracy, K., Baker, S., LoCastro, J., Mezinskis, J., Simon, S. & Somoza, E. (2000) The substance Clinical Global Impression Scale: measuring global functioning in substance related clinical trials. NIDA Research Monograph, 180, 169.
36. Williams, J. B. (1988) A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry, 45, 742-747.
37. Yamagata, K., Andreasson, K. I., Kaufman, W. E., Barnes, C. A. & Worley, P. F. (1993) Expression of mitogen-inducible clyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 11, 371-386.